S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission
Yanis Boumber,Hagop M. Kantarjian,Jeffrey L. Jorgensen,Sijin Wen,Stefan Faderl,Ryan J. Castoro,Jane Autry,Guillermo Garcia-Manero,Gautam Borthakur,Elias Jabbour,Zeev Estrov,Jorge E. Cortes,Jean Pierre J. Issa,Farhad Ravandi +13 more
TL;DR: A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission finds no significant difference between the two treatment regimens.
Journal ArticleDOI
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.
Uri Rozovski,George A. Calin,Tetsuro Setoyama,Lucilla D’Abundo,David Harris,Ping Li,Zhiming Liu,Srdana Grgurevic,Alessandra Ferrajoli,Stefan Faderl,Jan A. Burger,Susan O'Brien,William G. Wierda,Michael J. Keating,Zeev Estrov +14 more
TL;DR: The presence of activated STAT3 has a profound effect on miR expression in CLL cells, and putative STAT3 binding sites in 160 promoter regions of 200 miRs are identified, including miR-21, MiR-29, andMiR-155, whose levels have been reported to be upregulated in Cll.
Journal ArticleDOI
STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.
Zhiming Liu,Inbal Hazan-Halevy,David Harris,Ping Li,Alessandra Ferrajoli,Stefan Faderl,Michael J. Keating,Zeev Estrov +7 more
TL;DR: In this paper, the unphosphorylated (U) signal transducer and activator of transcription (STAT)-3 protein and U-STAT3 was reported to activate NF-κB in CLL.
Journal ArticleDOI
Phase II Study of Fludarabine, Cytarabine (Ara-C), Cyclophosphamide, Cisplatin and GM-CSF (FACPGM) in Patients With Richter's Syndrome or Refractory Lymphoproliferative Disorders
Apostolia Maria Tsimberidou,Susan O'Brien,Jorge E. Cortes,Stefan Faderl,Michael Andreeff,Hagop M. Kantarjian,Michael J. Keating,Francis J. Giles +7 more
TL;DR: FACPGM had very limited activity and significant toxicity in a cohort of patients with heavily pretreated refractory lymphoproliferative disorders.
Journal ArticleDOI
Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
Ohad Benjamini,Theresa Liu Dumlao,Hagop M. Kantarjian,Susan O'Brien,Guillermo Garcia-Manero,Stefan Faderl,Jeffrey L. Jorgensen,Rajyalakshmi Luthra,Rebecca Garris,Deborah A. Thomas,Partow Kebriaei,Richard E. Champlin,Elias Jabbour,Jan A. Burger,Jorge E. Cortes,Farhad Ravandi +15 more
TL;DR: The combination of HyperCVAD regimen with dasatinib is effective in patients with relapsed Ph‐positive ALL and CML‐LB.